TY  - JOUR
AU  - Lopez-Huertas, Maria Rosa
AU  - Jiménez-Tormo, Laura
AU  - Madrid-Elena, Nadia
AU  - Gutiérrez, Carolina
AU  - Rodríguez-Mora, Sara
AU  - Coiras, Mayte
AU  - Alcamí, José
AU  - Moreno, Santiago
PY  - 2017
DO  - 10.1038/s41598-017-02634-y
SN  - 2045-2322
UR  - http://hdl.handle.net/20.500.12105/7333
AB  - A potential strategy to cure HIV-1 infection is to use latency reversing agents (LRAs) to eliminate latent reservoirs established in resting CD4+ T (rCD4+) cells. As no drug has been shown to be completely effective, finding new drugs and combinations...
LA  - eng
PB  - Nature Publishing Group
KW  - Maraviroc
KW  - Bryostatin
KW  - HIV latency
KW  - HIV cure
KW  - LRA
KW  - Bryostatins
KW  - CCR5 Receptor Antagonists
KW  - CD4-Positive T-Lymphocytes
KW  - Cell Proliferation
KW  - Chemokine CCL19
KW  - Gene Expression Regulation
KW  - HIV-1
KW  - Humans
KW  - Interleukin-7
KW  - Maraviroc
KW  - NF-kappa B
KW  - Primary Cell Culture
KW  - Protein Kinase C
KW  - Receptors, CCR5
KW  - Signal Transduction
KW  - Virus Latency
KW  - Virus Replication
KW  - Host-Pathogen Interactions
TI  - The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
TY  - journal article
ER  -